Target Experimental data Clinical data
Ab (Mabthera)                CD20+ lymphocytes Lymphoma + +
Immunotoxin (CAT- 3888, CAT- 8015)Antibody-drug conjugate (Brentuxi-mab)                CD22+ lymphocytes (Lymphoma, leukemia) CD30+ lymphocytes (Hodgkin lymphoma) + + (+) (+)
Ab (HER2/neu) Toxin (orellanine) HER2+ tumor cells Kidney cancer/tubulecells + + + -
Radiotherapy lymph nodes/lymphoma Hodgkin’s disease     + +
Platinol Testicular cancer/ Teratoma + +
6-OH DOPA Melanoma + -
Ab (CTLA4)      T cell function Autoimmune reaction Melanoma, lung, kidney cancer + +
Ab (PD-1) T cell function Autoimmune reaction Melanoma, lung, kidney cancer + +
T-cell (transplantation) Leukemia (graft vs. host) + +
Table 1: Examples of therapies that, either through experimental or clinical data, exploit the hypothesis that by injuring the cell of origin of the tumor, the tumor could also respond to therapy. Ab=antibody, + = positive relationship, (+)= studies underway, - = no studies performed yet .